Marksans Pharma strengthens European presence with €7.5 million QliniQ acquisition - CNBC TV18
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
Quince Therapeutics has entered a merger acquisition of Quince Therapeutics, a healthcare services other business in California, for $undisclosed. Quince Therapeutics operates in the healthcare services other segment, with corporate activities and contractual obligations that support its operating platform. The healthcare M&A rationale centers on consolidating Quince Therapeutics’ assets, intellectual property, and compliance framework to strengthen future execution in CA acquisitions. The merger acquisition is announced as a merger acquisition, structured through merger sub entities and subject to customary closing conditions, with merger consideration, share conversions, and treatment of company convertible notes and options outlined in the agreement.
Filed under
Powered by Tentt
Tentt builds and operates managed deal origination services for PE firms, M&A advisors, and commercial lenders. We map the target universe, monitor signals, and execute outreach — white-labelled to your firm.
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
Marksans Pharma→QliniQ
Jun 1, 2026
Frazier Healthcare Partners→Altruix
May 31, 2026
Signos
May 31, 2026
Sterling Bay→Pacific Center
May 29, 2026